Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 7:14:1360663.
doi: 10.3389/fonc.2024.1360663. eCollection 2024.

Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015

Bing-Qian Tian #  1 , Shu-Wen Wang #  2 , Jing-Ying Xu  2 , San-Gang Wu  3 , Juan Zhou  2
Affiliations

Trends in survival of ovarian clear cell carcinoma patients from 2000 to 2015

Bing-Qian Tian et al. Front Oncol. .

Abstract

Purpose: To analyze changes in survival outcomes in patients with ovarian clear cell carcinoma (OCCC) treated consecutively over a 16-year period using a population-based cohort.

Methods: We conducted a retrospective analysis of OCCC from 2000 to 2015 using data from the Surveillance, Epidemiology, and End Results (SEER) program. The ovarian cancer-specific survival (OCSS) and overall survival (OS) were analyzed according to the year of diagnosis. Joinpoint Regression Program, Kaplan-Meier analysis, and multivariate Cox regression analyses were used for statistical analysis.

Results: We included 4257 patients in the analysis. The analysis of annual percentage change in OCSS (P=0.014) and OS (P=0.006) showed that patients diagnosed in later years had significantly better outcomes compared to those diagnosed in early years. The results of the multivariate Cox regression analyses showed that the year of diagnosis was the independent prognostic factor associated with OCSS (P=0.004) and had a borderline effect on OS (P=0.060). Regarding the SEER staging, the OCSS (P=0.017) and OS (P=0.004) of patients with distant stage showed a significant trend toward increased, while no significant trends were found in the survival of patients with localized or regional stage diseases. Similar trends were found in those aged <65 years or those treated with surgery and chemotherapy. However, no statistically significant changes in the survival rate were found in those aged ≥65 years or those receiving surgery alone regardless of SEER stage during the study period.

Conclusions: Our study observed a significant increase in the survival outcomes in OCCC from 2000 to 2015, and patients aged <65 years and those with distant stage experienced a greater improvement in survival.

Keywords: SEER; annual percentage change; clear cell carcinoma; ovarian cancer; survival trend.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
The flowchart of the cohort selection.
Figure 2
Figure 2
Annual percent change (APC) in 3-year ovarian cancer-specific survival (A) and overall survival (B) from 2000 to 2015.
Figure 3
Figure 3
The impact of the years of diagnosis on ovarian cancer-specific survival (A) and overall survival (B) in the entire cohort.
Figure 4
Figure 4
Annual percent change (APC) in 3-year ovarian cancer-specific survival (A) and overall survival (B) according to SEER staging from 2000 to 2015.
Figure 5
Figure 5
The impact of the years of diagnosis on ovarian cancer-specific survival and overall survival in patients with localized [(A), ovarian cancer-specific survival; (B), overall survival], regional [(C), ovarian cancer-specific survival; (D), overall survival], and distant stage [(E), ovarian cancer-specific survival; (F), overall survival].
Figure 6
Figure 6
Annual percent change (APC) in 3-year ovarian cancer-specific survival (A) and overall survival (B) according to age at diagnosis from 2000 to 2015.
Figure 7
Figure 7
The impact of the years of diagnosis on ovarian cancer-specific survival and overall survival in patients aged <65 years [(A), ovarian cancer-specific survival; (B), overall survival] and those aged ≥65 years [(C), ovarian cancer-specific survival; (D), overall survival].
Figure 8
Figure 8
Annual percent change (APC) in 3-year ovarian cancer-specific survival and overall survival according to SEER staging in patients aged <65 years [(A), ovarian cancer-specific survival; (B), overall survival] and aged ≥65 years [(C), ovarian cancer-specific survival; (D), overall survival] from 2000 to 2015.
Figure 9
Figure 9
Annual percent change (APC) in 3-year ovarian cancer-specific survival (A) and overall survival (B) according to treatment receipt from 2000 to 2015.
Figure 10
Figure 10
The impact of the years of diagnosis on ovarian cancer-specific survival and overall survival in patients treated with surgery alone [(A), ovarian cancer-specific survival; (B), overall survival] and surgery + chemotherapy [(C), ovarian cancer-specific survival; (D), overall survival].
Figure 11
Figure 11
Annual percent change (APC) in 3-year ovarian cancer-specific survival and overall survival according to SEER stage in patients treated with surgery alone [(A), ovarian cancer-specific survival; (B), overall survival] and surgery + chemotherapy [(C), ovarian cancer-specific survival; (D), overall survival].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. . Ovarian cancer statistics, 2018. CA Cancer J Clin. (2018) 68:284–96. doi: 10.3322/caac.21456 - DOI - PMC - PubMed
    1. Shah S, Cheung A, Kutka M, Sheriff M, Boussios S. Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health. (2022) 19:8113. doi: 10.3390/ijerph19138113 - DOI - PMC - PubMed
    1. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO classification of tumours of female reproductive organs. 4th ed. Lyon: IACR; (2014) p. 11–40.
    1. Hollis RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Cancer Lett. (2023) 555:216057. doi: 10.1016/S0140-6736(18)32552-2 - DOI - PubMed
    1. Aliyuda F, Moschetta M, Ghose A, Sofia Rallis K, Sheriff M, Sanchez E, et al. . Advances in ovarian cancer treatment beyond PARP inhibitors. Curr Cancer Drug Targets. (2023) 23:433–46. doi: 10.2174/1568009623666230209121732 - DOI - PubMed

LinkOut - more resources